



**Vivimed**

Date:13/02/2013

To

BSE Limited  
Listing Department  
P.J.Towers,Dalal Street,  
Mumbai – 400001

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

BSE - XXXX Code : 532660

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on February 13, 2013, inter alia, have resolved and taken note of/approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the Unaudited financial results for the Quarter ended December 31,2012 attached herewith;
2. The acquisition of the 100% shareholding, subject to the execution of a shareholders' agreement, related documentation and any other legal and regulatory approvals, of Finoso Pharma Private Limited ("Finoso) a Hyderabad based company, engaged in pharmaceutical development services, for an aggregate consideration of Rs.15,00,00,000 (Rupees fifteen Crores Rupee Only) payable in the form of cash, stock (shares of VIVIMED LABS LTD) and deferred milestone payments.

**ABOUT FINOSO:**

Finoso is a pharmaceutical development services Company, founded by Dr K R Kumar, a reputed technocrat who has built an experienced team, has established a portfolio of global client relationships. The services include formulation development, analytical development, regulatory filings and quality development



1



Vivimed

FINOSO has existing infrastructure at Alexandria Knowledge Park, Turkpally, Hyderabad, which can be leveraged within the full value chain of product development services including formulation dossiers, and out-licensing to support Vivimed Labs' pharmaceutical division strategy both in regulated and semi-regulated markets.

The aggregate acquisition consideration of Rs 15 Crores will comprise, subject to receiving shareholders' approval, execution of documentation and compliance with applicable law: (a) an issue of 142,857 equity shares of Rs 10/- each at a price of Rs 350/- per share to the shareholders of Finoso; and (b) and balance consideration of Rs 10 crores in the form of cash or equivalents in one or more tranches linked to milestones to be agreed.

3. Considered/approved the Notice to take the consent of members for further issue of Shares to Finoso Pharma Private Limited's share holders in Extra-ordinary General Meeting to be held on March 12<sup>th</sup>, 2013 .
4. Accepted the Resignation of Shri. C.Ramakrishna as a Director of the Company w.e.f. closing of business hours on January 11, 2013

The Board has placed on record its appreciation for the valuable contribution made by Shri. C.Ramakrishna in steering the Company on its growth path over the years.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

  
SANTOSH VARALWAR  
MANAGING DIRECTOR & CEO



**VIVIMED LABS LIMITED**  
**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED December 31st, 2012**

INR in Lacs

Sl. No.	Particulars	3 Months Ended			9 Months Ended		Previous Year Ended
		31.12.2012 (Unaudited)	30.09.2012 (Unaudited)	31.12.2011 (Unaudited)	31.12.2012 (Unaudited)	31.12.2011 (Unaudited)	31.03.2012 (Audited)
<b>1</b>	<b>Income From Operations</b>						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	27,211.94	26,608.92	16,601.08	81,072.52	41,725.38	66,831.38
	(b) Other Operating Income	226.85	973.71	158.41	1,381.41	178.20	268.23
	<b>Total Income From Operations (Net)</b>	<b>27,438.79</b>	<b>27,582.63</b>	<b>16,959.49</b>	<b>82,453.93</b>	<b>41,903.58</b>	<b>67,099.61</b>
<b>2</b>	<b>Expenses</b>						
	a. Cost of Raw Materials Consumed	13,990.81	12,497.70	8,958.74	40,457.96	24,048.38	31,573.68
	b. Purchase of Stock in Trade	-	-	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(45.48)	523.15	(717.61)	(2,496.96)	(2,037.42)	(1,835.31)
	d. Employee Benefit Expenses	932.73	1,260.34	835.59	3,597.40	2,034.60	3,422.45
	e. Depreciation and Amortisation Expenses	1,429.18	1,408.79	689.95	4,248.97	1,333.17	2,678.94
	f. Other Expenditure	8,840.77	7,932.45	4,561.61	25,597.64	8,277.82	16,640.79
	<b>Total Expenses</b>	<b>25,153.03</b>	<b>23,600.44</b>	<b>14,325.28</b>	<b>71,405.02</b>	<b>34,656.55</b>	<b>56,480.55</b>
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>2,285.76</b>	<b>3,982.19</b>	<b>2,631.21</b>	<b>11,048.91</b>	<b>7,247.03</b>	<b>10,619.06</b>
<b>4</b>	<b>Other Income</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>2,285.76</b>	<b>3,982.19</b>	<b>2,631.21</b>	<b>11,048.91</b>	<b>7,247.03</b>	<b>10,619.06</b>
<b>6</b>	<b>Finance Costs</b>	<b>984.19</b>	<b>1,075.40</b>	<b>585.85</b>	<b>3,648.65</b>	<b>2,027.64</b>	<b>2,837.54</b>
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>1,301.57</b>	<b>2,906.79</b>	<b>2,045.36</b>	<b>7,400.26</b>	<b>5,219.39</b>	<b>7,781.52</b>
<b>8</b>	<b>Exceptional items</b>	-	-	-	-	-	-
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>1,301.57</b>	<b>2,906.79</b>	<b>2,045.36</b>	<b>7,400.26</b>	<b>5,219.39</b>	<b>7,781.52</b>
<b>10</b>	<b>Tax Expenses</b>	<b>(391.28)</b>	<b>353.09</b>	<b>440.07</b>	<b>540.75</b>	<b>1,735.31</b>	<b>1,467.84</b>
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>1,692.85</b>	<b>2,553.70</b>	<b>1,605.29</b>	<b>6,859.51</b>	<b>4,084.08</b>	<b>6,313.68</b>
<b>12</b>	<b>Extraordinary Items (net of tax expenses Rs..... Lacs)</b>	-	-	-	-	-	-
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	<b>1,692.85</b>	<b>2,553.70</b>	<b>1,605.29</b>	<b>6,859.51</b>	<b>4,084.08</b>	<b>6,313.68</b>
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>	-	-	-	-	-	-
<b>15</b>	<b>Minority Interest</b>	-	-	-	-	-	-
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>1,692.85</b>	<b>2,553.70</b>	<b>1,605.29</b>	<b>6,859.51</b>	<b>4,084.08</b>	<b>6,313.68</b>
<b>17</b>	<b>Paid up Equity Share Capital (Face value of Rs 10/- each)</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>	-	-	-	-	-	<b>32,753.20</b>
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)</b>	-	-	-	-	-	-
	(a) Basic	12.15	18.33	11.52	49.23	29.31	45.31
	(b) Diluted	10.54	15.90	9.99	42.71	25.42	39.31

1. The above Consolidated Unaudited Financial Results for the Quarter ended December 31, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on February 13, 2013.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA INC, (iii) Klar sehen Private Limited, (iv) Octavian Nobel Labs Private Limited, (v) Vivimed Holdings Limited, with its step down subsidiaries (i) Vivimed Labs Europe Limited (ii) Vivimed Labs Mauritius Limited and its step down subsidiaries (a) Vivimed Labs UK Limited (b) Vivimed Labs Spain S.L with its further step down subsidiaries (i) Union Quimica Farmaceutica S.A. (ii) Holiday International Limited with its further step down subsidiary (i) Quimica Mexico S.A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO



Place: Hyderabad

Date: 13.02.2013




**VIVIMED LABS LIMITED**  
**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE**  
**LISTING AGREEMENT**

(INR in Lacs)

Particulars	3 Months ended		9 Months Ended		ended
	Unaudited		Unaudited		Audited
	31.12.2012	31.12.2011	31.12.2012	31.12.2011	31-03-2012
<b>1. Segment Revenue</b> (Net Sales/Income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	9,552.25	8,397.60	35,292.35	25,533.50	33,626.26
b. Pharma Business	17,659.69	8,403.50	45,780.17	16,191.87	33,205.12
<b>Total</b>	<b>27,211.94</b>	<b>16,801.10</b>	<b>81,072.52</b>	<b>41,725.38</b>	<b>66,831.38</b>
Less : Inter Segment Revenue		-		-	
<b>Net sales / Income from Operations</b>	<b>27,211.94</b>	<b>16,801.10</b>	<b>81,072.52</b>	<b>41,725.38</b>	<b>66,831.38</b>
<b>2. Segment Results (Profit)(+)/Loss(-) before tax and interest from each segment</b>					
a. Speciality Chemicals Business	1,425.20	1,382.90	5,291.45	4,509.95	6,006.97
b. Pharma Business	860.55	1,248.30	5,757.45	2,737.08	4,612.10
<b>Total</b>	<b>2,285.75</b>	<b>2,631.20</b>	<b>11,048.91</b>	<b>7,247.03</b>	<b>10,619.06</b>
Less: 1. Interest	984.19	585.85	3,648.65	2,027.64	2,837.54
2. Other Un-allocable Expenditure net off	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>1,301.56</b>	<b>2,045.35</b>	<b>7,400.26</b>	<b>5,219.39</b>	<b>7,781.52</b>
<b>3. Capital Employed</b>					
a. Speciality Chemicals Business	78,450.64	55,117.30	78,450.64	55,117.30	68,235.00
b. Pharma Business	47,961.24	41,954.30	47,961.24	41,954.30	40,330.20
<b>Total</b>	<b>126,411.87</b>	<b>97,071.60</b>	<b>126,411.87</b>	<b>97,071.60</b>	<b>108,565.20</b>

Place : Hyderabad  
Date : 13/02/2013

For VIVIMED LABS LIMITED  
  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



INR in Lacs

Sl. No.	Particulars	3 Months Ended			9 Months Ended		Previous Year Ended
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income From Operations</b>						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	11,413.05	10,968.42	9,275.63	31,487.53	29,179.40	38,289.99
	(b) Other Operating Income	68.43	155.57	9.36	262.93	25.90	41.96
	<b>Total Income From Operations (Net)</b>	<b>11,481.48</b>	<b>11,123.99</b>	<b>9,284.99</b>	<b>31,750.46</b>	<b>29,205.30</b>	<b>38,331.95</b>
<b>2</b>	<b>Expenses</b>						
	a. Cost of Raw Materials Consumed	6,464.67	6,047.12	5,581.04	18,987.60	18,177.50	22,930.02
	b. Purchase of Stock in Trade	-	-	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in Progress and Stock in Trade	484.36	644.46	(199.00)	(859.80)	(828.20)	(156.78)
	d. Employee Benefit Expenses	311.96	414.23	286.77	1,067.93	823.19	1,057.86
	e. Depreciation and Amortisation Expenses	385.00	380.50	209.81	1,137.73	598.96	1,055.10
	f. Other Expenditure	1,779.31	1,491.75	1,702.53	5,313.78	4,924.60	6,058.23
	<b>Total Expenses</b>	<b>9,425.30</b>	<b>8,977.86</b>	<b>7,583.06</b>	<b>25,607.24</b>	<b>23,605.90</b>	<b>30,944.43</b>
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>2,056.18</b>	<b>2,146.13</b>	<b>1,701.93</b>	<b>6,143.22</b>	<b>5,599.40</b>	<b>7,387.52</b>
<b>4</b>	<b>Other Income</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>2,056.18</b>	<b>2,146.13</b>	<b>1,701.93</b>	<b>6,143.22</b>	<b>5,599.40</b>	<b>7,387.52</b>
<b>6</b>	<b>Finance Costs</b>	<b>787.10</b>	<b>690.81</b>	<b>519.64</b>	<b>2,362.92</b>	<b>1,803.00</b>	<b>2,253.49</b>
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>1,269.08</b>	<b>1,455.32</b>	<b>1,182.29</b>	<b>3,780.30</b>	<b>3,796.40</b>	<b>5,134.02</b>
<b>8</b>	<b>Exceptional items</b>	-	-	-	-	-	-
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>1,269.08</b>	<b>1,455.32</b>	<b>1,182.29</b>	<b>3,780.30</b>	<b>3,796.40</b>	<b>5,134.02</b>
<b>10</b>	<b>Tax Expenses</b>	<b>243.70</b>	<b>537.88</b>	<b>236.55</b>	<b>992.83</b>	<b>741.60</b>	<b>1,092.57</b>
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>1,025.37</b>	<b>917.37</b>	<b>945.74</b>	<b>2,787.46</b>	<b>2,964.80</b>	<b>4,041.46</b>
<b>12</b>	<b>Extraordinary Items (net of tax expenses Rs. .... Lacs)</b>	-	-	-	-	-	-
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	<b>1,025.37</b>	<b>917.37</b>	<b>945.74</b>	<b>2,787.46</b>	<b>2,964.80</b>	<b>4,041.46</b>
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>	-	-	-	-	-	-
<b>15</b>	<b>Minority interest</b>	-	-	-	-	-	-
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>1,025.37</b>	<b>917.37</b>	<b>945.74</b>	<b>2,787.46</b>	<b>2,964.80</b>	<b>4,041.46</b>
<b>17</b>	<b>Paid up Equity Share Capital (Face value of Rs 10/- each)</b>	<b>1393.39</b>	<b>1393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>	<b>1,393.39</b>
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>	-	-	-	-	-	<b>26,201.50</b>
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) (of Rs. .... / each) (not annualised)</b>						
	(a) Basic	7.36	6.58	6.79	20.00	21.28	29.00
	(b) Diluted	6.38	5.71	5.89	17.36	19.46	25.16

1. The above Standalone Unaudited Financial Results for the Quarter ended December 31st, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on February 13, 2013.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place: Hyderabad  
Date: 13/02/2013

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO





VIVIMED LABS LIMITED

SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

(INR in Lacs)

Particulars	3 Months ended		9 Months Ended		Year Ended
	Unaudited		Unaudited		Audited
	31.12.2012	31.12.2011	31.12.2012	31.12.2011	31-03-2012
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	8,853.10	6,697.29	24,283.87	21,215.43	27,873.35
b.Pharma Business	2,559.94	2,578.34	7,203.66	7,963.99	10,416.65
<b>Total</b>	<b>11,413.04</b>	<b>9,275.63</b>	<b>31,487.53</b>	<b>29,179.42</b>	<b>38,289.99</b>
Less, Inter Segment Revenue	-	-	-	-	-
<b>Net sales / Income from Operations</b>	<b>11,413.04</b>	<b>9,275.63</b>	<b>31,487.53</b>	<b>29,179.42</b>	<b>38,289.99</b>
<b>2. Segment Results (Profit) (+) / Loss (-)</b> before tax and interest from each segment					
a.Speciality Chemicals Business	1,481.47	1,079.92	4,805.43	3,682.92	4,970.17
b.Pharma Business	574.70	622.02	1,337.78	1,826.51	2,417.35
<b>Total</b>	<b>2,056.17</b>	<b>1,701.93</b>	<b>6,143.21</b>	<b>5,509.43</b>	<b>7,387.52</b>
Less: 1.Interest	787.10	519.64	2,362.92	1,803.01	2,253.49
2.Other Un-allocable Expenditure	-	-	-	-	-
3.Un-allocable Income	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>1,269.07</b>	<b>1,182.30</b>	<b>3,780.29</b>	<b>3,706.42</b>	<b>5,134.03</b>
<b>3. Capital Employed</b>					
a.Speciality Chemicals Business	79,486.78	58,960.00	79,486.78	58,960.00	64,436.00
b.Pharma Business	7,068.48	9,188.48	7,068.48	9,188.48	6,003.20
<b>Total</b>	<b>86,555.26</b>	<b>68,148.48</b>	<b>86,555.26</b>	<b>68,148.48</b>	<b>70,439.20</b>

Place : Hyderabad  
Date : 13/02/2013

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



Part II					
Select Information for the Quarter Ended 31/12/2012					
	Particulars	3 months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Previous Year ended 31/03/2012
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	<b>Public shareholding</b>				
	Number of Shares	7642776	76,41,852	78,57,899	73,42,476
	Percentage of Shareholding	54.85 %	54.84	56.39	54.85
	<b>Promoter and Promoter Group Shareholding</b>				
	<b>(a) Pledged/ Encumbered</b>				
	Number of Shares	1577455	1577455	1052455	10,52,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	25.07	25.07	17.32	16.73
	Percentage of shares (as a % of the total share capital of the company)	11.32	11.32	7.55	7.55
	<b>(b) Non -encumbered</b>				
	Number of Shares	47,13,711	47,14,635	50,23,588	52,39,011
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	74.93	74.93	82.68	83.27
	Percentage of shares (as a % of the total share capital of the company)	33.83	33.84	36.05	37.60

	Particulars	3 months ended 31/12/2012
<b>B</b>	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil

*[Handwritten signature]*

